914835-38-4

Upstream product

• 112182-51-1 6-bromo-2-phenylquinolin-4(1H)-one 
• 438452-29-0 1-tert-butyl 2-methyl (2S,4S)-4-{[(4-bromo-phenyl)sulfonyl]oxy}-pyrrolidine-1,2-dicarboxylate 
• 106-40-1 4-bromo-aniline 
• 94-02-0 ethyl 3-oxo-3-phenylpropionate 
• 20364-59-4 6-bromo-2-phenylquinolin-4-ol 

Downstream Products

• 914835-51-1 1-t-butyl 2-methyl (2S,4R)-4-[(2-phenyl-6-vinylquinolin-4-yl)oxy]pyrrolidine-1,2-dicarboxylate 
• 914835-64-6 methyl (4R)-4-[(2-phenyl-6-vinylquinolin-4-yl)oxy]-L-prolinate chloride 
• 914836-16-1 methyl (2R,4S,7S)-7-butyl-6,9-dioxo-22-phenyl-3,4,6,7,8,9,12,13,14,15,16,17-dodecahydro-2H,11H-18,20-ethanediylidene-2,5-methanopyrido[4,3-κ][1,10,3,6]dioxadiazacyclohenicosine-4-carboxylate 
• 914835-77-1 methyl-N-[(hept-6-enyloxy)carbonyl]-L-norleucyl-(4R)-4-[(2-phenyl-6-vinylquinolin-4-yl)oxy]-L-prolinate 

Relevant academic research and scientific papers

Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease

Molecular modeling of inhibitor bound full length HCV NS3/4A protease structures proved to be a valuable tool in the design of a new series of potent NS3 protease inhibitors. Optimization of initial compounds provided 25a. The in vitro activity and select

HCV NS3 PROTEASE INHIBITORS

The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections. I